Bayer spends $100m on haemophilia development in Berkeley
Bayer has announced it will create a $100m (€94m) product testing site in California for its haemophilia A pipeline.
Archives for April 15, 2015
Dispatches from BPI 2015
Breakthrough barriers: Seeking fast track review means betting on data says Roche
To benefit from breakthrough therapy designation (BTD) pharma companies must be willing “bet on the right data” according to Roche, which says this could be a challenge for smaller firms.